Key statistics dashboard for Prelude Therapeutics Incorporated (PRLD). Valuation multiples (P/E, P/B, EV/EBITDA), profitability margins, financial-health ratios, per-share metrics and stock-level data in one consolidated view — the snapshot quantitative analysts and value investors check first.
Prelude Therapeutics, Inc. is a clinical-stage precision oncology company focused on identifying and developing innovative, targeted cancer treatments for patient populations with unmet medical needs. Its pipeline includes PRT543, currently undergoing Phase 1 clinical evaluation for certain solid tumors and myeloid malignancies. Another asset, PRT811, is also in Phase 1 trials, targeting various solid tumors, notably glioblastoma multiforme.
Stock Data
| Price | $4.47 |
| Market Cap | $254M |
| Beta | 0.71 |
| Exchange | NASDAQ |
| Country | US |
Valuation Multiples
| P/E Ratio | -5.72 |
| Price / Book | 3.33 |
| P/S | 11.48 |
| P/FCF | -7.74 |
| Dividend Yield | 0.00% |
Profitability
| Gross Margin | 98.26% |
| EBIT Margin | -269.75% |
| EBITDA Margin | -262.67% |
| Operating Margin | -300.56% |
| Net Margin | -269.75% |
Financial Health
| Current Ratio | 4.07 |
| Quick Ratio | 4.07 |
| Cash Ratio | 0.69 |
| Debt / Equity | 0.13 |
| Debt / Assets | 9.32% |
| Interest Coverage | 0.00 |
| Piotroski F-Score | 3 |
| Altman Z-Score | -7.34 |
Per-Share Data
| Revenue per share | 0.23 |
| Book Value per share | 1.36 |
| Cash per share | 1.54 |
| FCF per share | -0.34 |
| Tangible Book Value per share | 1.36 |
| Dividend per share | 0.00 |
Analyst Consensus
| Strong Buy | 0 |
| Buy | 5 |
| Hold | 1 |
| Sell | 2 |
| Strong Sell | 0 |
| Total analysts | 8 |
| Avg rating (1-5) | 0.38 |
Related companies: AVTX · CRBU · ENTA · EPRX · FHTX · IMRX · IVA
Explore sector: Healthcare · Biotechnology
More sections of PRLD: Overview · Financials · Valuation · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks